ScreenerHero

LEXX Lexaria Bioscience Corp.

NAS · US · Healthcare · Biotechnology · lexariabioscience.com
3.200USD-7.51%Mkt Cap: 6.74M $P/E: —

Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.47BUSDP/E 29.3
MRNA
Moderna, Inc.
$78.65BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.14BUSDP/E 18.3
ARGX
argenx SE
$51.48BUSDP/E 31.2
ARGX
argenx SE
$48.23BUSDP/E 31.4
UCB
UCB SA
$41.82BUSDP/E 17.8
RVMD
Revolution Medicines, Inc.
$40.32BUSD
ONC
BeOne Medicines AG
$39.83BUSDP/E 62.6
RPRX
Royalty Pharma plc
$32.48BUSDP/E 29.9
ALNY
Alnylam Pharmaceuticals, Inc.
$30.04BUSDP/E 37.9
ROIV
Roivant Sciences Ltd.
$24.71BUSD
BNTX
BioNTech SE
$23.13BUSD
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
GMAB
Genmab A/S
$22.17BUSDP/E 28.4
INSM
Insmed Incorporated
$21.94BUSD
GMAB
Genmab A/S
$21.10BUSDP/E 29.1
ASND
Ascendis Pharma A/S
$14.65BUSDP/E 17.1
EXEL
Exelixis, Inc.
$14.62BUSDP/E 18.6
JAZZ
Jazz Pharmaceuticals plc
$14.44BUSDP/E 15.2
SMMT
Summit Therapeutics Inc.
$13.70BUSD

Key Statistics

Company
Market Cap6.74M USD
Enterprise Value1.43M USD
Revenue (TTM)194.00K USD
Gross Profit703.20K USD
Net Income (TTM)-11.90M USD
Revenue/Share0.13 USD
Last Price3.200 USD
Fiscal Year EndAug 2025
MR QuarterMay 2026
Employees7
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-8.31
PEG—
EV/EBITDA-0.19
EV/Revenue7.37
P/S35.18
P/B1.13
EPS (TTM)-5.10
EPS (Forward)-0.39
52W Range
2.7702% of range21.60
52W High21.60 USD
52W Low2.770 USD
Profitability
Gross Margin99.61%
Oper. Margin-3862.94%
EBITDA Margin0.00%
Profit Margin-1686.00%
ROE-398.10%
ROA-285.07%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-10.45M USD
CapEx (TTM)99.75K USD
FCF Margin-2416.61%
FCF Yield-69.55%
Net Debt-3.53M USD
Net Debt/EBITDA0.48
Balance Sheet
Debt/Equity0.04
Current Ratio10.60
Quick Ratio9.56
Book Value/Sh2.87 USD
Cash/Share2.19 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay DateJan 12, 2021
Splits
Last Split1:15
Split DateAug 3, 2026
Analyst Consensus
Rating0.0 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)82.50 USD
Upside (mean)+2478.1%
Target Range82.50 USD – 82.50 USD
# Analysts1
Ownership
Shares Out.2.11M
Float1.60M
Insiders3.32%
Institutions6.62%
Short Interest
Short Ratio1.6d
Short % Float8.75%
Short % Out.8.50%
Shares Short179.00K
Short (prev mo.)27.87K
Technical
SMA 506.924 (-53.8%)
SMA 2009.609 (-66.7%)
Beta0.60
S&P 52W Chg15.78%
Avg Vol (30d)69.24K
Avg Vol (10d)51.77K
Technical Indicators
RSI (14)36.7
MACD-1.2428
MACD Signal-1.3757
MACD Hist.+0.1329
BB Upper5.058 USD
BB Middle3.465 USD
BB Lower1.871 USD
BB Width91.99%
ATR (14)0.8037 USD
Vol Ratio (20d)0.31x